Prospective, randomized, double-blind, active-controlled, multicenter trial of abciximab and bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary interventions [PCI] (ISAR-REACT-4).

Trial Profile

Prospective, randomized, double-blind, active-controlled, multicenter trial of abciximab and bivalirudin in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary interventions [PCI] (ISAR-REACT-4).

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2012

At a glance

  • Drugs Abciximab (Primary) ; Heparin (Primary) ; Bivalirudin
  • Indications Embolism and thrombosis; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ISAR-REACT-4
  • Most Recent Events

    • 29 Aug 2012 1-Year results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 23 Nov 2011 Primary endpoint composite of death, larger recurrent myocardial infarction, urgent target vessel revascularisation or mmajor bleed event rates has not been met.
    • 13 Nov 2011 Trial design and rationale reported at the 84th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top